Fuchs Endothelial Corneal Dystrophy (FECD) - Epidemiology Forecast - 2034

Fuchs Endothelial Corneal Dystrophy (FECD) - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that the Total Diagnosed Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM were ~18.9 million in 2022 and these cases are going to increase during the forecast period (2023–2034). This increase in growth can be attributed to growing awareness, ultimately leading to an increase in the diagnosed prevalence of FECD.

According to DelveInsight’s analysis, the Total Diagnosed Prevalent Cases of FECD in the US was found to be nearly 6.5 million in 2022 and is estimated to increase with a significant CAGR throughout the forecast period.

In 2022, the Total Diagnosed Prevalent Cases of FECD was approximately 9.2 million in EU4 and the UK, which is anticipated to increase during the study period [2020–2034].

As per DelveInsight’s estimates, Japan accounted for nearly 17% of the Total Diagnosed Prevalent Cases of FECD in the 7MM in 2022.

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy (FECD) – Epidemiology – 2034” report delivers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology of Fuchs Endothelial Corneal Dystrophy in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Fuchs Endothelial Corneal Dystrophy Disease Understanding

Fuchs Endothelial Corneal Dystrophy Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive hereditary disease affecting the cornea's endothelial layer. It is characterized by corneal edema, guttae formation, reduced visual acuity, and can lead to corneal blindness. FECD is more common in women, and its prevalence varies geographically in the 7MM. FECD is associated with genetic factors, with mutations in genes like COL8A2, SLC4A11, TCF4, and ZEB1 implicated in its development.

Fuchs Endothelial Corneal Dystrophy Diagnosis

Diagnosis of FECD involves clinical examination, in vivo imaging, and laboratory examination of removed corneas. Currently, slit lamp examination, specular microscopy, corneal thickness measurement, and confocal microscopy are used to identify FECD. There is a huge unmet medical need to improve the sensitivity of testing in the early stages. Although various tools are developed to improve disease diagnosis at an early stage such as deep learning algorithms and techniques like Scheimpflug tomography and anterior segment optical coherence tomography (AS-OCT), there is still a need to improve the availability and accessibility of these image analysis tools for early detection, monitoring of disease progression, and customized therapeutic interventions.

Further details related to diagnosis are provided in the report…

Fuchs Endothelial Corneal Dystrophy Epidemiology

For the purpose of designing the patient-based model for Fuchs Endothelial Corneal Dystrophy (FECD), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of FECD, Gender-specific Cases of FECD, Age-specific Cases of FECD, and Grade-specific Cases of FECD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

DelveInsight’s analyst estimate that approximately 18.9 million Diagnosed Prevalent Cases of FECD were found in 2022 in the 7MM.

The United States exhibited the highest diagnosed prevalent population of FECD, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Diagnosed Prevalent Cases of FECD in the US was around 6.5 million in 2022 and is projected to increase during the forecast period owing to the increasing awareness among the prevalent population.

According to DelveInsight’s estimates, the Total Diagnosed Prevalent Cases of FECD in EU4 and the UK were found to be 9.2 million in 2022. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of FECD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.

The estimates show the Total Diagnosed Prevalent Cases of FECD in Japan was found to be around 3 million in 2022, which is estimated to decrease by 2034 because of the decreasing country population.

The Gender-specific Cases of FECD in the 7MM were ~12.3 million for females and ~6.6 million for males in 2022 and are expected to increase within the forecast period (2023–2034). The increased prevalence in females is likely due to a combination of factors, including gender differences in behavior and neural development, and others.

According to the analysis performed by DelveInsight's experts, the Age-specific Cases of FECD were categorized into 40–49, 50-59, 60-69, 70-79, and =80 years. The higher number of cases (~1.9 million) was accounted for by the 50-59 year age group in 2022 in the US.

The Grade-specific Cases of FECD were categorized into Grade 1–3 and Grade 4–6. According to DelveInsight estimates, patients with Grade 1–3 FECD were higher (~6.8 million) than patients with Grade 4–6 FECD (~2.4 million) in the EU4 and the UK.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Jules Stein Eye Institute/UCLA, Los Angeles, Fight for Sight, New York, Department of Pharmacology and Biochemistry, UT Southwestern Medical Center, Texas, Philadelphia Eye Associates and Wills Eye Hospital, Philadelphia, Eye Center, Faculty of Medicine, University of Freiburg, Freiburg, Moorfields Eye Hospital, London, Kyoto Prefectural University of Medicine, Kyoto, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Fuchs Endothelial Corneal Dystrophy, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Fuchs Endothelial Corneal Dystrophy Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of FECD

Gender-specific Cases of FECD

Age-specific Cases of FECD

Grade-specific Cases of FECD

Fuchs Endothelial Corneal Dystrophy Report Key Strengths

12 years Forecast

The 7MM Coverage

Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation

Fuchs Endothelial Corneal Dystrophy Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Fuchs Endothelial Corneal Dystrophy? What will be the growth opportunities across the 7MM concerning the patient population of Fuchs Endothelial Corneal Dystrophy?

What is the historical and forecasted Fuchs Endothelial Corneal Dystrophy patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of FECD in Japan lower than the US?

Which country has a high patient share for FECD?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Fuchs Endothelial Corneal Dystrophy prevalence cases in varying geographies over the coming years.

A detailed overview of Gender, Age and Grade-specific diagnosed prevalence of FECD.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Fuchs Endothelial Corneal Dystrophy Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Fuchs Endothelial Corneal Dystrophy (FECD) cases in 2022?

The highest cases of Fuchs Endothelial Corneal Dystrophy was found in the Germany among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Fuchs Endothelial Corneal Dystrophy (FECD) cases in 2022?

The highest cases of Fuchs Endothelial Corneal Dystrophy were found in the US among the 7MM in 2022.